AbCellera is a Canadian biotechnology company headquartered in Vancouver, built around a proprietary antibody discovery platform that it licenses to pharmaceutical and biotech partners developing new drug candidates. Listed on Nasdaq under the ticker ABCL.O, the company gained widespread recognition during the COVID-19 pandemic as the discoverer of bamlanivimab, an antibody treatment developed in partnership with Eli Lilly and Company, which brought both revenue and visibility to a business that had previously operated largely below mainstream investor radar.
The underlying business model is distinctive: rather than advancing drugs through the full clinical pipeline itself, AbCellera acts as an upstream discovery partner, taking royalties and milestones as its partners progress candidates towards commercialisation. That royalty-driven structure gives the company long-term revenue potential largely decoupled from the operational complexity of running clinical trials, though near-term income can be lumpy and heavily dependent on partner development timelines.
Please note this is marketing communication, not recommendation or advice.
računi klijenata
FxPro pruža usluge online trgovine korisnicima još od 1999. i trenutno posluje u 173 države svijeta.
Nagrade
FxPro u svom polju stalno dobiva priznanja te je do danas osvojio više od 145 međunarodnih nagrada koje prepoznaju kvalitetu njegovih usluga.
služba za korisnike
Naša marljiva ekipa podrške koja govori više jezika neprestano se trudi kako bi vam pružila iznimnu razinu pomoći.
regulacija djelatnosti
FxPro posluje pod strogim regulatornim nadzorom u više jurisdikcija, uključujući ovlaštenje FCA u Ujedinjenom Kraljevstvu — jednog od najpouzdanijih financijskih regulatora na globalnoj razini.
